C hronic renal insufficiency (CRI) is a well-established risk factor and predictor of mortality in patients with coronary artery disease. [1][2][3][4][5][6][7][8] However, the impact of varying stages of CRI in patients with the entire acute coronary syndrome (ACS) spectrum has been less extensively studied.
In-hospital Major Clinical Outcomes in Patients With
RESULTS:Of 6518 consecutive patients with ACS, 2828 (43%) had mild CRI, 1304 (20%) had moderate CRI, and 345 (5%) had severe CRI. In CRI groups, patients were older and had a higher prevalence of hypertension, diabetes mellitus, and dyslipidemia. On admission, these patients had a higher resting heart rate and frequently had atypical and delayed presentations. Compared with the normal estimated glomerular filtration group, CRI groups were less likely to receive antiplatelet drugs, β-blockers, angiotensinconverting enzyme inhibitors, and statins and were less likely to undergo coronary angiography. In-hospital heart failure, cardiogenic shock, and major bleeding episodes were significantly higher in all CRI groups. In multivariate analysis, mild, moderate, and severe CRI were associated with a higher adjusted odds ratio (OR) of death (mild: OR, 2.1; 95% confidence interval [CI], 1.2-3.7; moderate: OR, 6.7; 95% CI, 3.9-11.5; and severe: OR, 12.0; 95% CI, 6.6-21.7).CONCLUSION: Across the ACS spectrum, patients with CRI had a worse risk profile, had more atypical and delayed presentations, and were less likely to receive evidence-based therapy. Chronic renal insufficiency of varying stages is an independent predictor of in-hospital morbidity and mortality.Mayo Clin Proc. 2010;85(4):332-340 ACS = acute coronary syndrome; CI = confidence interval; CrCl = creatinine clearance; CRI = chronic renal insufficiency; eGFR = estimated glomerular filtration rate; GRACE = Global Registry of Acute Coronary Events; Gulf RACE = Gulf Registry of Acute Coronary Events; MACE = major adverse cardiac event; NSTACS = non-ST-segment elevation ACS; OR = odds ratio; S Cr = serum creatinine; STEMI = ST-segment elevation myocardial infarctionThe objective of the current study was to evaluate the prognostic impact of the CRI stages on the in-hospital mortality and major adverse cardiac events (MACEs) across the ACS population, including patients with ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation ACS (NSTACS).